Burning Rock Biotech Ltd. (BNR) has released an update.
Burning Rock Biotech Ltd. reports a mixed financial performance for the fourth quarter and full year of 2023, with a decrease in overall revenue but a significant increase in pharma services contracts and revenue from pharma R&D services. The company achieved organizational optimization aimed at profitability and saw a breakthrough with its multi-cancer detection blood test. Despite a net loss and reduced revenue in its central laboratory business, new partnerships and increased demand in its in-hospital business offer a positive outlook.
For further insights into BNR stock, check out TipRanks’ Stock Analysis page.
